FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4244516808> ?p ?o ?g. }

• W4244516808 abstract "Abstract OBJECTIVE: To examine patient/caregiver preference for key attributes of treatments for spinal muscular atrophy (SMA). BACKGROUND: In the rapidly evolving SMA treatment landscape, it is critically important to understand how attributes of potential treatments may impact patient/caregiver choices. DESIGN/METHODS: A discrete choice experiment survey was developed based on qualitative interviews. Patients with SMA (18 years) and caregivers of patients were recruited through a U.S. patient organization. Respondents made choices in each of 12 sets of hypothetical treatments. The relative importance of five treatment characteristics was compared (measured by regression coefficients [RC] of conditional logit models): (1) improvement or stabilization of motor function, (2) improvement or stabilization of breathing function, (3) indication for all ages or pediatric patients only, (4) route of administration (repeated intrathecal [IT] injections, one-time intravenous [IV] infusion, daily oral delivery) and (5) potential harm (mild, moderate, serious/life threatening). RESULTS: Patient ages ranged from less than 1 to 67 years (n=101, 65 self-reported and 36 caregiver-reported) and 64 were female. Total SMA subtypes included: type 1 (n=21), type 2 (n=48), type 3 (n=29), other (n=3). Prior spinal surgery was reported in 47 patients. Nusinersen and onasemnogene abeparvovec-xioi use were reported in 59 and 10 patients, respectively. Improvement in motor and breathing function was highly valued (RC: 0.65, 95% confidence interval [CI]: 0.47–0.83 and RC: 0.79, 95% CI: 0.60–0.98, respectively). Oral medication and one-time infusion were strongly preferred over repeated IT injections (RC: 0.80, 95% CI: 0.60–0.98 and RC: 0.51, 95% CI: 0.30–0.73, respectively). Patients least preferred an age-restricted label/approved use ( 2 years of age) (RC: -1.28, 95% CI: -1.47 to -1.09). Cross-attributes trade-off decision suggested a lower willingness for a high-risk therapy despite additional efficacy gain. For some patients, there may be willingness to trade off additional gains in efficacy for a change in route of administration from repeated intrathecal administration to oral medication. CONCLUSIONS: Improvements in motor/breathing function, broad indication, oral or one-time infusion, and minimal risk were preferred treatment attributes. Treatment decisions should be made in clinical context and be tailored to patient needs." @default.
• W4244516808 created "2022-05-12" @default.
• W4244516808 creator A5016640472 @default.
• W4244516808 creator A5021113768 @default.
• W4244516808 creator A5023375973 @default.
• W4244516808 creator A5049357754 @default.
• W4244516808 creator A5069523303 @default.
• W4244516808 creator A5082298749 @default.
• W4244516808 creator A5089652766 @default.
• W4244516808 date "2020-08-10" @default.
• W4244516808 modified "2023-09-28" @default.
• W4244516808 title "Treatment Preference Among Patients With Spinal Muscular Atrophy (SMA): A Discrete Choice Experiment" @default.
• W4244516808 doi "https://doi.org/10.21203/rs.3.rs-54165/v1" @default.
• W4244516808 hasPublicationYear "2020" @default.
• W4244516808 type Work @default.
• W4244516808 citedByCount "0" @default.
• W4244516808 crossrefType "posted-content" @default.
• W4244516808 hasAuthorship W4244516808A5016640472 @default.
• W4244516808 hasAuthorship W4244516808A5021113768 @default.
• W4244516808 hasAuthorship W4244516808A5023375973 @default.
• W4244516808 hasAuthorship W4244516808A5049357754 @default.
• W4244516808 hasAuthorship W4244516808A5069523303 @default.
• W4244516808 hasAuthorship W4244516808A5082298749 @default.
• W4244516808 hasAuthorship W4244516808A5089652766 @default.
• W4244516808 hasBestOaLocation W42445168081 @default.
• W4244516808 hasConcept C114614502 @default.
• W4244516808 hasConcept C126322002 @default.
• W4244516808 hasConcept C161921814 @default.
• W4244516808 hasConcept C1862650 @default.
• W4244516808 hasConcept C2778558090 @default.
• W4244516808 hasConcept C2779134260 @default.
• W4244516808 hasConcept C33923547 @default.
• W4244516808 hasConcept C39300077 @default.
• W4244516808 hasConcept C42219234 @default.
• W4244516808 hasConcept C44249647 @default.
• W4244516808 hasConcept C71924100 @default.
• W4244516808 hasConceptScore W4244516808C114614502 @default.
• W4244516808 hasConceptScore W4244516808C126322002 @default.
• W4244516808 hasConceptScore W4244516808C161921814 @default.
• W4244516808 hasConceptScore W4244516808C1862650 @default.
• W4244516808 hasConceptScore W4244516808C2778558090 @default.
• W4244516808 hasConceptScore W4244516808C2779134260 @default.
• W4244516808 hasConceptScore W4244516808C33923547 @default.
• W4244516808 hasConceptScore W4244516808C39300077 @default.
• W4244516808 hasConceptScore W4244516808C42219234 @default.
• W4244516808 hasConceptScore W4244516808C44249647 @default.
• W4244516808 hasConceptScore W4244516808C71924100 @default.
• W4244516808 hasLocation W42445168081 @default.
• W4244516808 hasLocation W42445168082 @default.
• W4244516808 hasLocation W42445168083 @default.
• W4244516808 hasOpenAccess W4244516808 @default.
• W4244516808 hasPrimaryLocation W42445168081 @default.
• W4244516808 hasRelatedWork W14533807 @default.
• W4244516808 hasRelatedWork W15672994 @default.
• W4244516808 hasRelatedWork W16019421 @default.
• W4244516808 hasRelatedWork W17458057 @default.
• W4244516808 hasRelatedWork W1916704 @default.
• W4244516808 hasRelatedWork W192909 @default.
• W4244516808 hasRelatedWork W5844979 @default.
• W4244516808 hasRelatedWork W6119913 @default.
• W4244516808 hasRelatedWork W7510026 @default.
• W4244516808 hasRelatedWork W13713547 @default.
• W4244516808 isParatext "false" @default.
• W4244516808 isRetracted "false" @default.
• W4244516808 workType "article" @default.